Erasca, Inc.
ERAS
Ранг среди акций
#3403
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Цена акции
$14.62
Рыночная капитализация
$5.11B
Изменение (1 день)
7.34%
Изменение (1 год)
494.31%
Страна
US
Торговля Erasca, Inc. (ERAS)
Категория
Healthcare
Коэффициент P/B для Erasca, Inc. (ERAS)
Коэффициент P/B на October 2026 TTM: 12.65
Согласно последним финансовым отчетам и цене акций Erasca, Inc., текущий коэффициент P/B (TTM) составляет 12.65. В конце 2023 он составлял 1.01.
История P/B для Erasca, Inc. с 2019 по 2026
Коэффициент P/B в конце каждого года
| Год | P/B | Изменить |
|---|---|---|
| 2026 (TTM) | 12.65 | 809.88% |
| 2024 | 1.39 | 37.19% |
| 2023 | 1.01 | -20.90% |
| 2022 | 1.28 | -68.58% |
| 2021 | 4.06 | -122.34% |
| 2020 | -18.19 | -88.07% |
| 2019 | -152.41 | 0.00% |
Коэффициент P/B для аналогичных компаний или конкурентов
| Компания | P/B | Разница P/B | Страна |
|---|---|---|---|
| 6.251 | -50.57% |
US
|
|
| 13.2547 | 4.80% |
US
|
|
| 4.208 | -66.73% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -51.12% |
NL
|
